Orexigen Prices Share Offering, Celgene Results Published: Healthcare Business Wrap

Orexigen Therapeutics (NASDAQ:OREX) prices an offering of 11 million shares at $5.50, which is just under Wednesday’s close at $5.52. The net proceeds will amount to $56.5 million, and there exists in addition a greenshoe option of 1.65 million shares. The offering comes on the back of the firm reporting that the FDA supports accelerating the application for its weight loss med Contrave.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Celgene Corporation (NASDAQ:CELG) reports that abstracts reviewing results from a phase III metastatic melanoma evaluation with Abraxane for the upcoming Society for Melanoma Research meeting are now published online in the organization’s official journal. Results indicated that the drug shows significant improvement in progression-free survival, when contrasted with standard chemotherapy in patients suffering from advanced melanoma.

Life Partners Holdings (NASDAQ:LPHI) has named Colette Pieper as its Chief Financial Officer. Prior to joining Life Partners, Pieper was the Accounting Financial Director for the insurance and financial services provider USAA, which is based in San Antonio. It is anticipated that she will join the firm on November 19th.

Don’t Miss: Pharmaceutical Drug Wars: Here Are Two Winners and One Loser.

More from The Cheat Sheet